Evidence for large-scale gene-by-smoking interaction effects on pulmonary function by Aschard, H. (Hugues) et al.
Tobacco
Evidence for large-scale gene-by-smoking
interaction effects on pulmonary function
Hugues Aschard,1,2* Martin D Tobin,3,4 Dana B Hancock,5
David Skurnik,6 Akshay Sood,7 Alan James,8,9 Albert Vernon Smith,10,11
Ani W Manichaikul,12,13 Archie Campbell,14,15 Bram P Prins,16
Caroline Hayward,17 Daan W Loth,18 David J Porteous,14,15
David P Strachan,19 Eleftheria Zeggini,16 George T O’Connor,20,21
Guy G Brusselle,18,22,23 H Marike Boezen,24,25 Holger Schulz,26,27
Ian J Deary,28,29 Ian P Hall,30 Igor Rudan31 Jaakko Kaprio,32,33,34
James F Wilson,31,17 Jemma B Wilk,20 Jennifer E Huffman,17
Jing Hua Zhao,35,36 Kim de Jong,24,25 Leo-Pekka Lyytik€ainen,37,38
Louise V Wain,3,4 Marjo-Riitta Jarvelin39,40,41,42 Mika K€aho¨nen,43
Myriam Fornage,44 Ozren Polasek31,45 Patricia A Cassano,46,47
R Graham Barr,48 Rajesh Rawal49,50,51 Sarah E Harris,14,28
Sina A Gharib,52 Stefan Enroth,53 Susan R Heckbert,55
Terho Lehtim€aki,37,38 Ulf Gyllensten,53
Understanding Society Scientific Group, Victoria E Jackson,3
Vilmundur Gudnason,10,11 Wenbo Tang,46,55 Jose´e Dupuis,20,56 Marıa
Soler Artigas,3 Amit D Joshi,1,2,57 Stephanie J London58† and
Peter Kraft1,2†
1Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA, 2Program in
Genetic Epidemiology and Statistical Genetics, Harvard TH Chan School of Public Health, Boston, MA,
USA, 3Genetic Epidemiology Group, Department of Health Sciences, University of Leicester, Leicester,
UK, 4National Institute for Health Research, Leicester Respiratory Biomedical Research Unit, Glenfield
Hospital, Leicester, UK, 5Behavioral and Urban Health Program, Behavioral Health and Criminal Justice
Research Division, Research Triangle Institute (RTI) International, Research Triangle Park, NC, USA,
6Division of Infectious Diseases, Brigham and Women Hospital, Harvard Medical School, Boston, MA,
USA, 7Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine,
University of New Mexico School of Medicine, Albuquerque, NM, USA, 8Department of Pulmonary
Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, 9School of Medicine
and Pharmacology, University of Western Australia, Crawley, Australia, 10Icelandic Heart Association,
Kopavogur, Iceland, 11Faculty of Medicine, University of Iceland, Reykjavik, Iceland,12Center for Public
Health Genomics, University of Virginia, Charlottesville, VA, USA, 13Department of Public Health
Sciences, Division of Biostatistics and Epidemiology, University of Virginia, Charlottesville, VA, USA,
14Centre for Genomic & Experimental Medicine, Institute of Genetics & Molecular Medicine, University
of Edinburgh, Edinburgh, UK, 15Generation Scotland, Centre for Genomic and Experimental Medicine,
University of Edinburgh, Edinburgh, UK, 16Department of Human Genetics, Wellcome Trust Sanger
VC The Author 2017. Published by Oxford University Press on behalf of the International Epidemiological Association 894
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
International Journal of Epidemiology, 2017, 894–904
doi: 10.1093/ije/dyw318
Advance Access Publication Date: 12 January 2017
Original article
Institute, Hinxton, UK, 17MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine,
University of Edinburgh, Edinburgh, UK, 18Department of Epidemiology, Erasmus Medical Center,
Rotterdam, The Netherlands, 19Population Health Research Institute, St George’s University of London,
London, UK, 20The National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, MA,
USA, 21The Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston,
MA, USA, 22Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium,
23Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands,
24University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen,
The Netherlands, 25University of Groningen, University Medical Center Groningen, Groningen Research
Institute for Asthma and COPD, Groningen, The Netherlands, 26Institute of Epidemiology I, Helmholtz
Zentrum Mu¨nchen, German Research Center for Environmental Health, Neuherberg, Germany,
27Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung
Research, Munich, Germany, 28Centre for Cognitive Ageing and Cognitive Epidemiology, University of
Edinburgh, Edinburgh, UK, 29Department of Psychology, University of Edinburgh, Edinburgh, UK, 30Division
of Respiratory Medicine, University of Nottingham, Queen’s Medical Centre, Nottingham, UK, 31Centre for
Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of
Edinburgh, Edinburgh, UK, 32Department of Public Health, University of Helsinki, Helsinki, Finland,
33Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland, 34National Institute for Health
and Welfare, Department of Health, Helsinki, Finland, 35MRC Epidemiology Unit, University of Cambridge
School of Clinical Medicine, Cambridge, UK, 36Institute of Metabolic Science, Biomedical Campus,
Cambridge, UK, 37Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland, 38Department
of Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland, 39Department of
Epidemiology and Biostatistics, MRC–PHE Centre for Environment & Health, School of Public Health,
Imperial College London, UK, 40Center for Life Course Epidemiology, Faculty of Medicine, University of
Oulu, Oulu, Finland, 41Biocenter Oulu, University of Oulu, Oulu, Finland, 42Unit of Primary Care, Oulu
University Hospital, Oulu, Finland, 43Department of Clinical Physiology, University of Tampere and
Tampere University Hospital, Tampere, Finland, 44Brown Foundation Institute of Molecular Medicine,
University of Texas Health Science Center at Houston, Houston, TX, USA, 45Faculty of Medicine,
University of Split, Split, Croatia, 46Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA,
47Department of Healthcare Policy and Research, Weill Cornell Medical College, NY, NY, USA,
48Departments of Medicine and Epidemiology, Columbia University Medical Center, 49Institute of Genetic
Epidemiology, Helmholtz Zentrum Mu¨nchen, German Research Center for Environmental Health,
Neuherberg, Germany, 50Research Unit of Molecular Epidemiology, Helmholtz Zentrum Mu¨nchen,
German Research Center for Environmental Health, Neuherberg, Germany, 51Institute of Epidemiology II,
Helmholtz Zentrum Mu¨nchen, German Research Center for Environmental Health, Neuherberg, Germany,
52Computational Medicine Core at Center for Lung Biology, Division of Pulmonary & Critical Care
Medicine, University of Washington, Seattle, WA, 53Department of Immunology, Genetics and Pathology,
Uppsala Universitet, Science for Life Laboratory, Uppsala, Sweden, 54Cardiovascular Health Research
Unit and Department of Epidemiology, University of Washington, Seattle, WA, USA, 55Boehringer
Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 56Department of Biostatistics, Boston University
School of Public Health, Boston, MA, USA, 57Division of Gastroenterology, Massachusetts General
Hospital, Boston, MA, USA. Human Services, Research Triangle Park, NC, USA and 58Epidemiology
Branch, National Institute of Environmental Health Sciences, National Institutes of Health, US
Department of Health and Human Services, Research Triangle Park, NC, USA
*Corresponding author. Department of Epidemiology, Harvard School of Public Health, Building 2, Room 205, 665
Huntington Avenue, Boston, MA 02115, USA. E-mail: haschard@hsph.harvard.edu
†These authors contributed equally to this work.
Accepted 10 October 2016
International Journal of Epidemiology, 2017, Vol. 46, No. 3 895
Abstract
Background: Smoking is the strongest environmental risk factor for reduced pulmonary
function. The genetic component of various pulmonary traits has also been demon-
strated, and at least 26 loci have been reproducibly associated with either FEV1 (forced
expiratory volume in 1 second) or FEV1/FVC (FEV1/forced vital capacity). Although the
main effects of smoking and genetic loci are well established, the question of potential
gene-by-smoking interaction effect remains unanswered. The aim of the present study
was to assess, using a genetic risk score approach, whether the effect of these 26 loci on
pulmonary function is influenced by smoking.
Methods: We evaluated the interaction between smoking exposure, considered as either
ever vs never or pack-years, and a 26-single nucleotide polymorphisms (SNPs) genetic
risk score in relation to FEV1 or FEV1/FVC in 50 047 participants of European ancestry
from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) and
SpiroMeta consortia.
Results: We identified an interaction (bint¼ –0.036, 95% confidence interval, –0.040 to
–0.032, P¼0.00057) between an unweighted 26 SNP genetic risk score and smoking sta-
tus (ever/never) on the FEV1/FVC ratio. In interpreting this interaction, we showed that
the genetic risk of falling below the FEV1/FVC threshold used to diagnose chronic ob-
structive pulmonary disease is higher among ever smokers than among never smokers.
A replication analysis in two independent datasets, although not statistically significant,
showed a similar trend in the interaction effect.
Conclusions: This study highlights the benefit of using genetic risk scores for identifying
interactions missed when studying individual SNPs and shows, for the first time, that
persons with the highest genetic risk for low FEV1/FVC may be more susceptible to the
deleterious effects of smoking.
Key words: FEV1/FVC, smoking, gene–environment interaction, genetic risk score
Introduction
Spirometric measures of pulmonary function, such as the
forced expiratory volume in 1 second (FEV1) or its ratio
with the forced vital capacity (FEV1/FVC), form the basis of
the diagnosis of chronic obstructive pulmonary disease
(COPD).1–3 Pulmonary function measures are also used clin-
ically to monitor severity and control of asthma and other re-
spiratory diseases and are independent risk factors for
mortality.1–3 Pulmonary function is strongly influenced by
cigarette smoking and by multiple low-penetrance genetic
variants. Indeed, genome-wide association studies (GWAS)
of marginal genetic effects (i.e. not including interaction ef-
fects between genetic variants and smoking) have identified
at least 26 loci associated with FEV1 or FEV1/FVC in the
general population.4 However, the interplay between genetic
factors and environmental exposures has not been well
Key Messages
• Spirometric measures of pulmonary function are influenced by both smoking and genetics. This paper reports a gen-
etic risk score-by-ever smoking interaction on FEV1/FVC (forced expiratory volume in 1 second/forced vital capacity).
• In individuals of European ancestry, the reduction in FEV1/FVC as a result of smoking was greater among individuals
who are genetically predisposed to lower FEV1/FVC ratio.
• Genetic risk score-by-ever smoking interaction can allow the identification of subgroups in the population whose gen-
etic background makes them more susceptible to the deleterious effects of smoking.
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established for pulmonary function or its associated traits.
More broadly, although considerable efforts have been made
to identify interaction effects between genetic variants and
environmental exposures across the wide range of human
traits and diseases,5,6 such investigations have been mostly
unsuccessful in detecting robust gene–environment inter-
actions.5,7 The well-established effect of cigarette smoking
on numerous human health outcomes8 makes it a serious
candidate for identification of novel gene–environment inter-
actions, especially for pulmonary traits.
Hypothesizing the presence of single nucleotide polymorph-
ism (SNP)-by-smoking interaction, Hancock et al.9 performed
a genome-wide interaction study of pulmonary function, mod-
elling single SNP main effects and their interactions with
smoking in 50047 participants of European ancestry across
19 studies within the Cohorts for Heart and Aging Research
in Genomic Epidemiology (CHARGE)10 and SpiroMeta con-
sortia11—the largest genome-wide interaction study of pul-
monary function as modified by smoking to date. However,
rather than focusing on the interaction effects per se, they per-
formed a meta-analysis of the joint test of SNP main effects
and SNP-by-smoking interaction effects to improve power for
identifying genetic variants associated with pulmonary func-
tion.12,13 Although they reported new candidate variants based
on this joint test, the study did not identify any SNPs with
genome-wide significant interaction with smoking.
Here, we explored gene-by-smoking interaction effects
limited to genetic variants previously found to be associ-
ated with pulmonary function in standard marginal effects
GWAS,4 therefore not including the new variants reported
by Hancock et al.9 based on the joint test of main effects
plus interaction. Specifically, we aimed to determine
whether smoking modifies the effect of established genetic
variants when considered singly or in combination using a
genetic risk score summarizing the genetic predisposition
to abnormal pulmonary function. The primary motivation
for using genetic risk score is statistical power.14,15 Indeed,
several genetic risk score-by-exposure interactions have al-
ready been identified in cases where single SNPs did not
show evidence for statistically significant interactions.16–21
Genetic risk score-by-exposure interaction testing expands
on the principle of omnibus test while leveraging the as-
sumption that, for a given choice of coded alleles, most
interaction effects will have the same direction. This is
similar to burden tests that have been widely used for rare
variant analysis22 where a single parameter can accumulate
evidence for association without increasing the number of
degrees of freedom. When interaction effects are null on
average (i.e. if interaction effects are both negative and
positive so that the sum of interaction coefficients tend to
zero), the single SNP approach will generally outperform
the risk score-based approach. Conversely, if interaction
effects tend to be in the same direction, the risk score-
based approach can have dramatically higher power.14
Methods
Study sample
The present analysis relies on the Hancock et al.9 genome-
wide meta-analysis for main genetic effects plus interaction
effects with smoking in relation to pulmonary function
among 50 047 participants (56% women) of European an-
cestry from 19 studies. The mean age was 53 years at the
time of pulmonary function testing. Approximately 15%
were current smokers and 56% were ever smokers. Among
ever smokers, the average pack-years of smoking was 21.
Supplementary Table 3 (available as Supplementary data
at IJE online) provides the main characteristics of the stud-
ies included; complete details of study-specific pulmonary
function testing protocols have been published.4 For stud-
ies with spirometry at a single visit, we analysed FEV1/
FVC and FEV1 measured at that visit. For studies with
spirometry at more than one visit, measurements from the
baseline visit or the most recent examination with spirom-
etry data was used. Smoking history (current, former and
never smoking) was ascertained by questionnaire at the
time of pulmonary function testing. Pack-years of smoking
were calculated for current and past smokers by multiply-
ing smoking amount (packs per day) and duration (years
smoked). Approximately 2.5 million autosomal SNPs were
tested for interaction with smoking status (ever smoking vs
never smoking) and pack-years, for two outcomes: FEV1
and FEV1/FVC (see next section). We also used two inde-
pendent datasets of individuals of European ancestry to
test for replication. The first replication dataset included
8859 unrelated individuals, and the second dataset
included 9457 family-based individuals. The look-up was
done in the GWAS for marginal genetic effects done separ-
ately in ever and never smoker as part of a recent meta-
analysis of FEV1 and FEV1/FVC.
23
Single SNP-by-smoking interaction
The analysis performed in this study used summary statistics
data from the aforementioned meta-analysis of 19 studies
performed by Hancock et al.9 In brief, each of the 19 studies
derived the residuals of FEV1 and FEV1/FVC after regressing
out age, age2, sex, standing height, principal component
eigenvectors of genotypes and recruitment site if applicable.
The residuals were normalized using a rank-based inverse
normal transformation. Single SNP interaction effects were
assessed using the following model (see Supplementary Note,
available as Supplementary data at IJE online):
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Y  b0 þ bGGþ bGEkGEk þ
X
l¼1...3bElEl ; (1)
where bG and bEl are the main effect of the SNP G and ex-
posure El, bGEk is the interaction effect between G and ex-
posure Ek, and b0 the intercept.
Detailed description of studies used in the replication
analysis can be found in Soler Artigas et al.23 In brief, lin-
ear regression of age, age2, sex, height and principal com-
ponents for population structure was undertaken on FEV1
and FEV1/FVC separately for ever smokers and never
smokers. The residuals were normalized using a rank-
based inverse normal transformation, again separately in
ever smokers and never smokers. These transformed re-
siduals were then used as the phenotype for association
testing under an additive genetic model in each exposure
strata. Inference of the interaction effects from the
exposure-stratified analyses are described in the
Supplementary Note (available as Supplementary data at
IJE online).
Multivariate interaction analysis overview
First, we considered an unweighted genetic risk score-by-
smoking interaction where the risk score simply sums the
number of risk alleles (i.e. alleles associated with a lower
pulmonary function). This unweighted genetic risk score is
most powerful when the interaction effects have the same
direction as marginal SNP effects (i.e. the harmful effects
of smoking are magnified in individuals with a genetic pre-
disposition to reduced pulmonary function). Second, we
used a weighted genetic risk score where SNPs were
weighted by the absolute value of their marginal effect esti-
mates obtained from stage 1 screening of FEV1 and FEV1/
FVC from Soler Artigas et al.4 (Supplementary Table 1,
available as Supplementary data at IJE online). This
weighting scheme is most powerful when the magnitude of
interaction effects is proportional to the SNP marginal ef-
fects. Finally, for our third multivariate analysis, we
derived a standard omnibus test of all interaction effects.
This test will retain power in the presence of effects in both
directions or of different magnitudes. Although there is
strong correlation among the 12 tests performed (these
three models, considering interaction with two smoking
metrics, ever/never smoking or pack-years, for the two pul-
monary function metrics FEV1 and FEV1/FVC), we used a
stringent Bonferroni P-value correction threshold of
4 10–3 to account for multiple testing.
When raw data are available, the weighted genetic risk
score (GRS) is usually expressed as GRS¼Rm[wiGi],
where m is the number of SNPs included in the genetic risk
score and w¼ (w1,..wm) are the weights attributed to each
single SNP. Following previous notation, the test of inter-
action between the GRS and the exposure Ek can be
applied using the following model:
Y  c0 þ cGRS GRSþ cINT GRS Ek þ
X
l¼1...3cEl
 El ;
(2)
where c0, cGRS, cEl and cINT are the intercept, the main ef-
fect of the GRS, the main effect of the exposure El and the
interaction effect between Ek and the GRS, respectively.
However, because individual-level data were not directly
available, we performed the test of cINT from summary
statistics of interaction effects using an inverse-variance
weighted sum as proposed by Aschard.14 The chi-square
for the interaction term cINT was derived as follows:
v2int ¼
X
i¼1...m
wib^GiEk
r^2bGiEk
 !2
X
i¼1...m
w2
i
r^2bGiEk
; (3)
where b^GiEk and r^
2
bGiEk
are the estimated effects and vari-
ance of the interaction between the exposure Ek and the
SNP Gi obtained from Equation (1) and wi is the weight
applied to SNP Gi. Under the null hypothesis of no inter-
action effect, v2int follows a chi-squared distribution with
one degree of freedom.
The standard omnibus test of all interaction effects con-
sisted of evaluating jointly aGEk ¼ ðaG1Ek ; . . . ; aGmEkÞ
from the model:
Y  a0 þ
X
i¼1...m½aGi Gi
þ
X
i¼1...m½aGiEk Gi  Ek þ
X
l¼1...3aEl  El;
(4)
where a0, aGi , aEl and aGiEk are the intercept, the main ef-
fects of SNP Gi and the exposure El, and the interaction ef-
fect between Gi and Ek. Leveraging the independence
between the SNPs considered (a single SNP was selected
for each independent locus), we also derived the omnibus
test using summary statistics. Under this independence as-
sumption, the GiEk interaction terms would also be in-
dependents,14 so that it can be performed by summing the
chi-square from each univariate interaction test to form a
chi-square with m degrees of freedom as follows:
v2omnibus ¼
X
i¼1...m
b^
2
GiEk
r^2bGiEk
; (5)
where b^GiEk and r^
2
bGiEk
are the estimated effects and
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variance of the interaction between the exposure Ek and
the SNP Gi obtained from Equation (1).
Relative risk in ever smokers vs never smokers
GRS interaction effects can further be translated in terms of
risk prediction. For pulmonary function, low FEV1 or FEV1/
FVC increases the risk of death24 and together they form the
basis for the diagnosis of COPD.1–3 COPD stage 2 or higher
are defined by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) as FEV1/FVC< 0.70 and
FEV1< 80% of the predicted value. According to recent stud-
ies,2,25 between 5% and 20% of European ancestry adults
are expected to have FEV1/FVC< 0.70, depending on smok-
ing characteristics and age distribution. Several studies argue
for a more stringent threshold to define COPD25,26 based on
lower limit of normal predicted value, rather than a fixed ab-
solute value, to prevent disease misclassification.
To explore the impact of interaction effect on the risk
of disease, we derived the relative risk (RR) of having
FEV1/FVC below a given threshold (1%, 5% and 20%) in
ever smokers vs never smokers conditional on the un-
weighted GRS. This quantity is defined as the joint prob-
ability of having both FEV1/FVC in the interval [–1,
FEV1/FVCup] and the GRS in the interval [GRSlow,GRSup].
This can be expressed as the following integral:
ðFEV1=FVCup
1
ðGRSup
GRSlow
f1ðyjg; eÞ  f2ðgjeÞ dy dg; (6)
where y, e and g are FEV1/FVC, smoking status and the
GRS, respectively, and f1 and f2 are the probability density
function of y and g. The detailed derivation of the above
integral is available as Supplementary data at IJE online.
Results
We selected 26 loci previously found to be associated with
FEV1 or FEV1/FVC at genome-wide significance
(P< 5 10–8) in marginal association tests4,11,27 (i.e. not
including interaction effects with smoking exposures) and
replicated in the GWAS by Soler Artigas et al.,4 the largest
meta-analysis of marginal genetic effect conducted for
these two traits in the general population. Additional loci
for these two phenotypes have been identified in two recent
studies.28,29 However, these new loci were not included in
our analysis because both these studies used a large cohort
ascertained through smoking status. For each of the 26 se-
lected loci, we choose the SNP with the strongest evidence
for association (i.e. smallest P-value) with each of these
phenotypes. The final list included 26 SNPs per phenotype,
with only two SNPs being different between FEV1 and
FEV1/FVC as previously reported
4 (Supplementary Table
1, available as Supplementary data at IJE online).
Estimated interaction effects of these SNPs were extracted
from the meta-analysis summary statistics for the four tests
performed in the Hancock et al.9 analysis: SNP-by-
smoking status (ever smoking vs never smoking)
interaction effect on FEV1 and FEV1/FVC; and SNP-by-
smoking pack-years interaction effect on FEV1/FVC and
FEV1. As shown in Supplementary Table 2 (available as
Supplementary data at IJE online), nine SNPs showed
nominal significance (P< 0.05) out of the 104 tests per-
formed; however, none remained significant after account-
ing for multiple testing (Bonferroni corrected P-value
threshold of 5 10–4). The minimum P-value was observed
for the interaction between rs993925, near the TGFb2
gene, and smoking status on FEV1 [bint¼ –0.036, 95%
confidence interval (CI), –0.009 to –0.032, P¼ 0.007].
Next, using these data, we conducted three multivariate
(as opposed to single SNP) interaction analyses, testing
jointly for the interaction effects between those SNPs and
either smoking status or pack-years on the two phenotypes
(FEV1 and FEV1/FVC) for a total of 12 tests. As shown in
Table 1, none of the multivariate interaction tests with
pack-years was significant. However, four of the six multi-
variate interaction tests with smoking status (ever vs never)
showed nominal significance, and two tests for FEV1/FVC
had a P-value below the Bonferroni significance level (12
tests, P< 4 10–3). The strongest signal was observed for
the unweighted genetic risk score-by-smoking status inter-
action effect on FEV1/FVC (bint¼ –0.036, 95% CI –0.040
to –0.032, P¼ 0.00057). The Cochran’s Q test for hetero-
geneity of the interaction effect across studies was not sig-
nificant (P¼ 0.97) and the forest plot of study-specific
results did not display any obvious outlier (Supplementary
Figure 1, available as Supplementary data at IJE online).
The contrast between this significant risk score inter-
action and the absence of strong single SNP interaction ef-
fects can be explained by looking at the distribution of the
single SNP interaction effect estimates. Figure 1 shows this
distribution for the alleles associated with decreased FEV1/
FVC. It highlights that, although the 95% CI of most single
SNP interaction effects encompass the null (and therefore
the absence of significant single SNP interaction effect),
there is an enrichment for negative interaction effects.
Indeed, even a binomial test can be used to confirm the
unbalanced direction of interaction effects (18 of 26 inter-
actions are negative leading to a P-value of 0.014 for a bi-
nomial test with an expected equiprobable distribution of
0.5). The genetic risk score-based interaction test exploits
such enrichment by testing for the average interaction ef-
fect across all SNPs.14 As with any multivariate approach
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Table 1. Multivariate interaction tests of the 26 loci associated with pulmonary function
Outcome Exposure Test bˆint (CI) P-value
FEV1 Smoking status
a uGRS –0.0055 (–0.011, 2.710–5) 0.051
wGRS –0.21 (–0.40, –0.033) 0.020
CHISQ – – 0.49
FEV1 Pack-years uGRS –1.610–5 (–4.610–5, 1.410–5) 0.30
wGRS –6.510–4 (–1.610–3, 3.310–4) 0.19
CHISQ – – 0.46
FEV1/FVC Smoking status uGRS –0.0099 (–0.016, –0.0043) 0.00057
b
wGRS –0.21 (–0.33, –0.073) 0.0022b
CHISQ – – 0.026
FEV1/FVC Pack-years uGRS –4.4e-06 (–3.610–5, 2.710–5) 0.78
wGRS –6.510–5 (–8.010–4, 6.610–4) 0.85
CHISQ – – 0.53
uGRS is the genetic risk score using equal weights to all SNPs; wGRS is the genetic risk score weighted by effect estimates from the marginal screening; CHISQ
is the omnibus test of all interaction effects; bˆint is the estimated interaction effect between the GRS and the outcome; and CI is the confidence interval of that esti-
mate. Nominally significant tests are indicated in bold.
aSmoking status is defined as never smokers vs ever smokers.
bSignificant P-value after Bonferroni correction.
Figure 1. Distribution of interaction effects on FEV1/FVC.
Single SNP risk allele-by-smoking status (ever/never) interaction effect estimates (bint) and 95% confidence intervals are plotted by increasing values.
The unweighted genetic risk score-by-smoking status interaction is plotted at the bottom.
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based on a composite null hypothesis, this result indicates
that at least a subset of these 26 SNPs interact with smok-
ing status, but does not allow us to determine which or
how many SNPs are driving the genetic risk score-by-
smoking interaction. The three other sets of single SNP
interaction tests showed a similar (but not significant after
correction for multiple testing) trend with enrichment for
negative interactions (Supplementary Figures 2–4, avail-
able as Supplementary data at IJE online). We summarized
the contribution of the unweighted genetic risk score-by-
smoking interaction on FEV1/FVC in Table 2 and
Figure 2A. This indicates that the deleterious effect of
smoking is enhanced among carriers of the risk alleles or
equivalently that the deleterious effect of smoking is
reduced among subjects carrying the protective alleles.
We used two independent datasets, one of 8859 unre-
lated individuals and another of 9457 related individuals,
to test for independent replication of our results
(Supplementary Note, available as Supplementary data at
IJE online). Although the interaction effects were not sig-
nificant, both replication samples showed consistent nega-
tive GRS-by-ever smoking interaction effect on FEV1/FVC
(b^int¼ –0.0025, 95% CI –0.0165, 0.0115, P¼ 0.72 and
b^int¼ –0.0030, 95% CI –0.0214, 0.0154, P¼ 0.74, and
overall interaction effect in the combined replication data-
sets b^int¼ –0.0027, 95% CI –0.0136, 0.0082 P¼ 0.63) and
a Cochran’s Q test for heterogeneity showed no significant
difference in the three effect estimates (P¼ 0.51).
To quantify the impact of this result from a public health
perspective, we estimated the impact of the genetic risk
score-by-smoking interaction on having FEV1/FVC below
1%, 5% and 20% in the lower tails of the distribution in
the population. Specifically, we derived the RR of having
FEV1/FVC below these cut-off points (1%, 5% and 20%)
in ever smokers compared with never smokers. Figure 2B
quantifies the excess RR (i.e. the RR minus one) of individ-
uals across five GRS quintiles. It highlights the higher risk
associated with smoking among individuals carrying risk
alleles (i.e. alleles associated with poorer pulmonary func-
tion) as compared with individuals carrying protective al-
leles (i.e. alleles associated with better pulmonary function).
For example, among individuals with a GRS above the
80th percentile, smokers have on average a 26% excess RR
of having FEV1/FVC in the lowest 1% of the population
distribution, whereas ever smokers with a GRS below the
20th percentile have on average an 18% excess RR of fall-
ing in that same FEV1/FVC category compared with never
smokers. Applying the same approach for FEV1, we
observed a similar pattern (Supplementary Figure 5, avail-
able as Supplementary data at IJE online). However, as
expected, the lower magnitude of the genetic risk score-by-
ever smoking interaction on FEV1 implied a lower differ-
ence in RR between ever smokers and never smokers.
Discussion
Using the largest dataset to date of European ancestry par-
ticipants from the general population with pulmonary
Table 2. Summary of effect estimates for genetic risk score-
by-smoking status interaction on FEV1/FVC
Predictors Beta SD P-value
From the marginal exposure model
Pack-years –0.0030 0.00017 1.210–71
Current smoking –0.040 0.0047 7.710–18
Smoking statusa –0.0023 0.0046 0.61
From the interaction model
GRS –0.0363 0.0021 3.910–64
GRS Smoking statusa –0.0099 0.0029 5.710–4
GRS is the unweighted genetic risk score; beta is the effect estimates of
each predictor; and SD the standard deviation of the each beta.
aSmoking status was defined as never smokers vs ever smokers.
Figure 2. Overview of the unweighted genetic risk score-by-smoking
interaction effect on FEV1/FVC.
Upper panel (A) presents the distribution of the unweighted genetic risk
score (GRS, grey density plot) and the relationship between the un-
weighted GRS and standardized FEV1/FVC in ever smokers (dashed line)
and never smokers (solid line). Lower panel (B) shows the excess rela-
tive risk (RR) of having FEV1/FVC in the lowest 1%, 5% and 20% of the
population for ever smokers compared with never smokers, as stratified
by GRS quintiles.
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function (FEV1/FVC and FEV1), smoking and genetic data,
we identified a gene-by-smoking interaction effect on
FEV1/FVC by using a GRS composed of 26 SNPs identified
and replicated in a prior GWAS meta-analysis of marginal
genetic effects. To our knowledge, our study is the first to
report a synergistic action of genes and smoking on pul-
monary function (i.e. the reduction in FEV1/FVC as a re-
sult of smoking is greater among individuals who are
genetically predisposed to lower FEV1/FVC ratio). Our
study also highlights the importance of developing and
applying alternative strategies to evaluate interaction ef-
fects for lung phenotypes along with other complex traits
and diseases. The genetic risk score-based approach
enabled us to identify an interaction when the standard
univariate test (i.e. evaluating each single genetic variant
for interaction independently) failed to identify any
interactions.
Replication studies showed interaction effect estimates
in the same direction as the discovery study but were not
significant, and the magnitude of interaction effects were
substantially smaller. We acknowledge that, despite careful
evaluation of the interaction effects in the discovery sam-
ple, the observed signal might be overestimated or con-
founded by unmeasured complex factors. However, we
can a priori rule out a systematic bias of the single SNP
interaction effects in the discovery study, because the gen-
omic inflation factor k, defined as the ratio of the median
of the empirically observed distribution of the test statistic
to the expected median,30 was not substantially different
from 1 (k¼ 1.044 for FEV1/FVC and smoking status).
Instead, differences in significance and effect estimates
might be partly explained by the limited sample size in the
replication study and differences in the analytical design.
Indeed, the discovery analysis was performed using a satu-
rated model including three smoking exposures and expli-
citly modelled the interaction effect. In comparison, the
replication analysis was not adjusted for current smoking
status and pack-year, and the interaction effect was
approximated from analyses stratified by smoking status
outcome, which has some limitations (see Supplementary
Note and Supplementary Figure 6, available as
Supplementary data at IJE online). Previous work has
shown that combined analyses are more powerful when ef-
fects exist in both strata,31 as observed in discovery study.
Further, even with N¼ 18 316 individuals in the combined
replication population, we are underpowered. This sample
size provides less than 50% power, at nominal significance
of 5%, to detect interaction effects with the GRS.
Genetic risk score-by-exposure interaction can have
higher clinical value than the identification of single SNP-
by-exposure interaction by capturing a wealth of informa-
tion in a single measure to identify subgroups in the
population whose genetic background makes them more
susceptible to the deleterious effects of smoking.19,32,33
Indeed, if single SNP-by-smoking interactions are distrib-
uted unconditionally on the marginal genetic effect (i.e.
interaction effects are equally likely to be positive or nega-
tive given that the coded alleles are the risk alleles), the
genetic effect is expected to be similar between ever and
never smokers. The enrichment for negative interactions
we identified through our GRS approach reveals a stronger
genetic component among the ever smoker subgroup in the
population and can allow the implementation of more effi-
cient implementation of prevention strategies. For ex-
ample, in the public health setting, programmes targeting
smoking cessation campaigns to individuals who are genet-
ically predisposed to low pulmonary function may have a
stronger impact in preventing COPD.
Our results may also elucidate biological mechanisms
underlying the interplay between genes and smoking in
pulmonary function. In particular, the higher statistical
power for the genetic risk score-based interaction test
points towards the potential presence of an unmeasured
intermediate biomarker mediating the effect of the 26 loci
on FEV1/FVC. As shown in Figure 3, the most parsimoni-
ous model (i.e. the less complex following Occam’s razor)
that would explain multiple interactions going in the same
direction (Figure 1) implies that the genetic variants
Figure 3. Underlying causal model.
Potential causal diagrams underlying the gene and smoking interaction
effects on FEV1/FVC. Panel (A) presents a scenario where each genetic
variant influences the outcome through a SNP-specific pathway, and
interactions with the environmental exposure take place along these
pathways. Panel (B) presents an alternative (and simpler) model where
multiple genetic variants influence an unmeasured intermediate bio-
marker U, which effect on FEV1/FVC depends on smoking. In scenario
(A), the single SNP-by-smoking interaction test is the optimal approach,
whereas, in scenario (B), the single SNP-by-smoking interaction test
can become inefficient, and interaction would be easier to detect using
a genetic risk score-by-smoking interaction test, because it summarizes
all interaction effects in a single test.
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together influence an intermediate biomarker, which itself
interacts with smoking. Future studies with extended gen-
omic data, including transcriptomic, proteomic or metabo-
lomic data, might be able to further assess such an
hypothesis by evaluating (i) the effect of the GRS on those
biomarkers and (ii) testing for interactions between smok-
ing and the candidate biomarkers identified at step (i).
This study has some limitations. The 26 selected vari-
ants together explain a relatively small proportion of the
additive genetic variance in FEV1/FVC and in FEV1.
4
However, GWAS with increasing sample sizes will likely
continue to provide additional associated genetic variants
to further assess the role of SNP-by-smoking interaction ef-
fects on pulmonary phenotypes and may increase the gap
between smokers and never smokers to allow for a signifi-
cant impact in the clinic or at the population level.
Moreover, we focused on genetic variants previously found
to be associated at genome-wide significance level, but fu-
ture studies might consider less stringent criteria to select
genetic variants, including those with only suggestive evi-
dence, or alternatively candidate variants with functional
annotation relevant to the outcomes and exposures in
question. Obviously, the signal-to-noise ratio might de-
crease when relaxing the constraint on the SNP selection.
However, as we recently showed, additional gain in statis-
tical power might be achieved even if a substantial propor-
tion of the variants do not interact with the exposure.14
Finally, investigation of interaction effects with other en-
vironmental exposures such as second-hand smoke, air
pollution, asbestos or occupational risks may lead to a
more comprehensive understanding of the biological and
epidemiological significance of these variants.
In summary, the identification of interaction effects be-
tween genetic variants and environmental exposures in
human traits is recognized as extremely challenging, and
this quest has been mostly unsuccessful so far. In this
study, we discovered novel gene-by-smoking interactions
using risk scores that were not observed at the level of indi-
vidual genetic variants. This risk score analysis suggests
that persons with a greater genetic predisposition to low
pulmonary function are more susceptible to the deleterious
effects of smoking. By extension, the use of a GRS may
help predict which smokers will fall below thresholds that
establish the diagnosis of COPD.
Supplementary Data
Supplementary data are available at IJE online.
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